|Bid||4,790.00 x 6100|
|Ask||4,975.00 x 13000|
|Day's range||4,772.50 - 4,954.50|
|52-week range||3,996.00 - 5,520.00|
|PE ratio (TTM)||16.11|
|Earnings date||9 Nov 2017|
|Dividend & yield||2.79 (4.51%)|
|1y target est||67.31|
Bernstein sees opportunity in a buyout target.
AstraZeneca led the FTSE 100 higher on Friday after Bernstein Research said investors were wrong to write off the chances of another takeover approach. Bristol-Myers Squibb is seen as the most likely target ...
** Bernstein ups AstraZeneca to "outperform", citing big pipeline and potential take-out ** Broker sees co's LT EPS growth among the very best of the 9 major EI/US pharma cos it covers ** Bernstein ...